Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for young AML patients: targeted drug combo tested in phase 2 trial

NCT ID NCT06917911

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 39 times

Summary

This study tests two different drug combinations for younger adults with a specific type of acute myeloid leukemia (CBF-AML). One group gets standard chemotherapy plus a targeted antibody, while the other gets the same chemotherapy plus a newer targeted pill. The goal is to see which combination works better at clearing the cancer with fewer side effects. About 162 people will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Baptist Cancer Center-Grenada

    RECRUITING

    Grenada, Mississippi, 38901, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Baptist Memorial Hospital and Cancer Center-Collierville

    RECRUITING

    Collierville, Tennessee, 38017, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Baptist Memorial Hospital and Cancer Center-Desoto

    RECRUITING

    Southhaven, Mississippi, 38671, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Baptist Memorial Hospital and Cancer Center-Golden Triangle

    RECRUITING

    Columbus, Mississippi, 39705, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Baptist Memorial Hospital and Cancer Center-Memphis

    RECRUITING

    Memphis, Tennessee, 38120, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Baptist Memorial Hospital and Cancer Center-Oxford

    RECRUITING

    Oxford, Mississippi, 38655, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Baptist Memorial Hospital and Cancer Center-Union County

    RECRUITING

    New Albany, Mississippi, 38652, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Gundersen Lutheran Medical Center

    RECRUITING

    La Crosse, Wisconsin, 54601, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton

    RECRUITING

    Brighton, Michigan, 48114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Trinity Health IHA Medical Group Hematology Oncology - Canton

    RECRUITING

    Canton, Michigan, 48188, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

    RECRUITING

    Chelsea, Michigan, 48118, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

    RECRUITING

    Ypsilanti, Michigan, 48197, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Trinity Health Saint Joseph Mercy Oakland Hospital

    RECRUITING

    Pontiac, Michigan, 48341, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Trinity Health Saint Mary Mercy Livonia Hospital

    RECRUITING

    Livonia, Michigan, 48154, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

The condition(s) this trial relates to.

core binding factor acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.